Sarepta Therapeutics (SRPT) Stock Price, Quote & News

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dyst...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 274 4000

Website: www.sarepta.com

Address:

215 First Street, Suite 415, Cambridge, United States

UpTheIrons123 Jul. 4 at 8:58 PM

$SRPT new here what is the timing for the approval?

0 · Reply

MarianoItaliano Jul. 4 at 5:19 PM

$SRPT a lot of fud will resolve after Q1 2027

0 · Reply

cosmo42 Jul. 4 at 4:48 PM

$SRPT makes you wonder if there are any …….. between Kim and HC wainwright????

0 · Reply

cosmo42 Jul. 4 at 4:42 PM

$SRPT great Kim has a lapdog now @Princeredyr

0 · Reply

cosmo42 Jul. 4 at 4:39 PM

$SRPT Thai is starting problems even when markets are closed and on Independence Day ironically he left the free world to pursue who knows what. …. Just saying pharma defending Kim who has outrageous price targets and made up info.

0 · Reply

biomaster22 Jul. 4 at 1:01 PM

$SRPT Thaig you have finally showed your true colors antifa blm and pick any of these new anarchistic groups all originate from the far left, wake up or get out of this great country

1 · Reply

Thaigrlsrk Jul. 4 at 11:22 AM

$SRPT Organised online abuse is one of the core tactics of the modern far right, just as street violence was central to 20th century fascism. Ring a bell fred, Max, cosmo?

3 · Reply

cosmo42 Jul. 4 at 2:41 AM

$SRPT one day you might be right but until I see price over $30+ then 👇

0 · Reply

Thaigrlsrk Jul. 4 at 2:32 AM

$SRPT One of the big questions in my mind is if the MAD data for both drugs is good will Wainwright even know it's good.

1 · Reply

deweyeggbert Jul. 3 at 11:14 PM

$SRPT 3-4X 90 days.

0 · Reply

H.C. Wainwright says Sarepta news does not signal full approvals

Jun 30, 2026, 4:25 PM EDT - 4 days ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-06-30T12:35:47.000Z - 4 days ago

Sarepta announces FDA acceptance of sNDAs for AMONDYS 45, VYONDYS 53

Jun 30, 2026, 8:30 AM EDT - 4 days ago

Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®

Jun 8, 2026, 10:40 AM EDT - 26 days ago

Sarepta Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 10:00 AM EDT - 4 weeks ago

Sarepta Therapeutics Transcript: AGM 2026

Jun 1, 2026, 4:30 PM EDT - 4 weeks ago

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

2026-05-15T12:30:23.000Z - 7 weeks ago

Sarepta price target lowered to $19 from $20 at Evercore ISI

May 13, 2026, 4:30 PM EDT - 7 weeks ago

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

2026-05-07T00:41:58.000Z - 2 months ago

Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year

May 6, 2026, 4:30 PM EDT - 2 months ago

Sarepta Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Sarepta Therapeutics Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Sarepta Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

Sarepta Therapeutics Slides: Q1 2026

May 6, 2026, 4:05 PM EDT - 2 months ago

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Sarepta Therapeutics Proxy statement: Proxy filing

Apr 22, 2026, 8:30 AM EDT - 2 months ago

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

2026-04-16T16:20:19.000Z - 2 months ago

Roche decision could hurt Sarepta in U.S., says H.C. Wainwright

2026-04-07T15:08:48.000Z - 3 months ago

Sarepta price target raised to $19 from $18 at RBC Capital

2026-03-26T12:40:44.000Z - 3 months ago

Deutsche ups Sarepta target, says 35% stock rally overdone

2026-03-26T12:37:02.000Z - 3 months ago

Sarepta price target raised to $35 from $29 at Wedbush

2026-03-26T09:56:24.000Z - 3 months ago

Sarepta price target raised to $13 from $9 at Citi

2026-03-25T19:50:31.000Z - 3 months ago

Sarepta price target raised to $25 from $20 at Morgan Stanley

2026-03-25T14:10:14.000Z - 3 months ago

Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink

Mar 25, 2026, 8:30 AM EDT - 3 months ago

Sarepta Therapeutics Transcript: Study result

Mar 25, 2026, 8:30 AM EDT - 3 months ago

Sarepta Therapeutics Press release: Study result

Mar 25, 2026, 8:30 AM EDT - 3 months ago

Sarepta Therapeutics Slides: Study result

Mar 25, 2026, 8:05 AM EDT - 3 months ago

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Mar 24, 2026, 4:05 PM EDT - 3 months ago

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Mar 19, 2026, 8:30 AM EDT - 3 months ago

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

Mar 16, 2026, 8:33 AM EDT - 3 months ago

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Mar 3, 2026, 1:50 PM EST - 4 months ago

Sarepta Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 27, 2026, 9:00 AM EST - 4 months ago

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

Feb 26, 2026, 8:30 AM EST - 4 months ago

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

Feb 26, 2026, 5:05 AM EST - 4 months ago

Sarepta Therapeutics CEO Ingram to retire by year end

Feb 25, 2026, 4:30 PM EST - 4 months ago

Sarepta Therapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Sarepta Therapeutics Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Sarepta Therapeutics Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 4 months ago

Sarepta Therapeutics Slides: Q4 2025

Feb 25, 2026, 4:05 PM EST - 4 months ago

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

Feb 24, 2026, 9:07 AM EST - 4 months ago

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

Feb 24, 2026, 8:30 AM EST - 4 months ago

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 11, 2026, 8:30 AM EST - 5 months ago

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

Feb 4, 2026, 8:30 AM EST - 5 months ago

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

Jan 26, 2026, 8:53 AM EST - 5 months ago

Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys

Jan 26, 2026, 8:30 AM EST - 5 months ago

Sarepta Therapeutics Transcript: Study result

Jan 26, 2026, 8:30 AM EST - 5 months ago

Sarepta Therapeutics Press release: Study result

Jan 26, 2026, 8:30 AM EST - 5 months ago

Sarepta Therapeutics Slides: Study result

Jan 26, 2026, 8:10 AM EST - 5 months ago

Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows

Jan 26, 2026, 8:00 AM EST - 5 months ago

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

Jan 23, 2026, 4:05 PM EST - 5 months ago

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

Jan 12, 2026, 12:00 PM EST - 6 months ago

Sarepta Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:00 PM EST - 6 months ago

Sarepta Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:58 AM EST - 6 months ago

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Jan 12, 2026, 9:30 AM EST - 6 months ago

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Jan 7, 2026, 8:30 AM EST - 6 months ago

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

Jan 5, 2026, 8:30 AM EST - 6 months ago

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 7:00 AM EST - 7 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Nov 25, 2025, 8:57 AM EST - 7 months ago

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Nov 24, 2025, 7:30 AM EST - 7 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

ARWR

Nov 24, 2025, 7:30 AM EST - 7 months ago

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Nov 14, 2025, 2:54 PM EST - 8 months ago

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Nov 14, 2025, 2:08 PM EST - 8 months ago

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Nov 4, 2025, 9:55 AM EST - 8 months ago

Sarepta Therapeutics shares plunge after disappointing trial data

Nov 4, 2025, 6:20 AM EST - 8 months ago

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Nov 4, 2025, 4:27 AM EST - 8 months ago

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Nov 3, 2025, 6:26 PM EST - 8 months ago

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Nov 3, 2025, 4:30 PM EST - 8 months ago

Sarepta Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 8 months ago

Sarepta Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 8 months ago

Sarepta Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 8 months ago

Sarepta Therapeutics Slides: Q3 2025

Nov 3, 2025, 4:24 PM EST - 8 months ago

Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:05 PM EST - 8 months ago

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Oct 27, 2025, 4:05 PM EDT - 8 months ago

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Oct 23, 2025, 6:46 AM EDT - 9 months ago

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

BLSH DASH FLY IREN NEM OPEN QS

Oct 3, 2025, 8:30 AM EDT - 9 months ago

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Sep 5, 2025, 9:00 AM EDT - 10 months ago

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

Aug 25, 2025, 3:11 AM EDT - 11 months ago

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

Aug 23, 2025, 7:08 AM EDT - 11 months ago

SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)

Aug 21, 2025, 7:00 AM EDT - 11 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

UpTheIrons123 Jul. 4 at 8:58 PM

$SRPT new here what is the timing for the approval?

0 · Reply

MarianoItaliano Jul. 4 at 5:19 PM

$SRPT a lot of fud will resolve after Q1 2027

0 · Reply

cosmo42 Jul. 4 at 4:48 PM

$SRPT makes you wonder if there are any …….. between Kim and HC wainwright????

0 · Reply

cosmo42 Jul. 4 at 4:42 PM

$SRPT great Kim has a lapdog now @Princeredyr

0 · Reply

cosmo42 Jul. 4 at 4:39 PM

0 · Reply

biomaster22 Jul. 4 at 1:01 PM

$SRPT Thaig you have finally showed your true colors antifa blm and pick any of these new anarchistic groups all originate from the far left, wake up or get out of this great country

1 · Reply

Thaigrlsrk Jul. 4 at 11:22 AM

$SRPT Organised online abuse is one of the core tactics of the modern far right, just as street violence was central to 20th century fascism. Ring a bell fred, Max, cosmo?

3 · Reply

cosmo42 Jul. 4 at 2:41 AM

$SRPT one day you might be right but until I see price over $30+ then 👇

0 · Reply

Thaigrlsrk Jul. 4 at 2:32 AM

$SRPT One of the big questions in my mind is if the MAD data for both drugs is good will Wainwright even know it's good.

1 · Reply

deweyeggbert Jul. 3 at 11:14 PM

$SRPT 3-4X 90 days.

0 · Reply

StreakGeek Jul. 3 at 4:48 PM

Banked from @TopSarge alerts the last few weeks, timing’s been on point! Follow him so you don't miss out 🔥 $VKTX $RECAF $SRPT 3 good adds

0 · Reply

Hoganknowsbest Jul. 3 at 4:06 PM

$SRPT so moderna does a little more then this in revenue and at 70?

2 · Reply

cooler2 Jul. 3 at 3:32 PM

$SRPT - LETS GET A$250 BO PRICE IN HONOR OF OUR 250th. !!!! LETS GOOOO🚀🚀🚀

0 · Reply

free2dream Jul. 3 at 1:58 PM

$SRPT Sarepta should be your main pick prior earnings. The company valuation need to reprice - $200+ , should be valed same as $MRNA at $30B plus

0 · Reply

topstockalerts Jul. 3 at 12:55 AM

$SRPT every dip getting scooped… kinda telling

1 · Reply

LudwigVanBeethoven Jul. 3 at 12:36 AM

$SRPT the practical joke they play on us .. since .. June 2025

0 · Reply

4Reel Jul. 2 at 11:57 PM

$SRPT need to blow the queens up shorting this stock. Wainwright has a 5 dollar price target and most likely millions of shares short trying to hold this company down. They are also the HF that gives rediculous 20 or 30 dollar price targets for 2 and 3 dollar stocks. Make them pay next week. Out of all the hedge funds their opinion means the least on any stock imo. Make them pay next week 🙌

1 · Reply

TokyoJoeWasMyFriend Jul. 2 at 11:39 PM

$SRPT 2nd point of resistance today at the 200MA. A break takes it to 3rd point at $22.67 then off to the races. Unless the big news happens first. $IBB $XBI

0 · Reply

iceicemoney10 Jul. 2 at 9:22 PM

$SRPT good week , just good enough to keep us longs around 🤣 Happy 4th all 🇺🇸🇺🇸🍻

0 · Reply

KY3000 Jul. 2 at 8:51 PM

$SRPT crazy block buys, heaven or hell next week

0 · Reply

KY3000 Jul. 2 at 8:38 PM

$MRNA $SRPT 2 of the most targeted companies by RFK FDA, c-suite of both companies gangsters.

0 · Reply

KY3000 Jul. 2 at 8:35 PM

$SRPT rest of 2026 goal, make HC Wainwright pay… Moderna type flip. Doug a gangster, went all in against RFK FDA

0 · Reply

Market Cap	2.04B
Revenue (ttm)	2.20B
Net Income (ttm)	-713.41M
EPS (ttm)	N/A
PE Ratio	28.44
Forward PE	4.60
Profit Margin	-32.45%
Debt to Equity Ratio	0.56

Volume	4,358,100
Avg Vol	3,399,046
Day's Range	N/A - N/A
Shares Out	105.58M
Stochastic %K	93%
Beta	0.21
Analysts	Sell
Price Target	$21.83